Exploring Evaxion Biotech A/S (EVAX) Investor Profile: Who’s Buying and Why?

Are you keeping a close watch on the biotech sector and wondering who's investing in Evaxion Biotech A/S (EVAX)? Have you noticed the stock's wild ride, plummeting by 93.79% from $21.10 per share on April 18, 2024, to just $1.31 on April 17, 2025? With a market cap of just $8.20 million and a recent history of public offerings, including a $10.8 million raise in January 2025, understanding the investor profile is more critical than ever. Are institutional investors losing faith, or are strategic players making calculated moves in anticipation of Evaxion's AI-powered immunotherapy breakthroughs? Read on to discover who the major players are, what motivates their investments, and what it all means for the future of EVAX.

Evaxion Biotech A/S (EVAX) Who Invests in [Company Name] and Why?

Understanding the investor profile of Evaxion Biotech A/S (EVAX) provides crucial insights into the company’s market perception and future prospects. Investors are drawn to EVAX for various reasons, reflecting diverse investment strategies and motivations.

Key investor types in Evaxion Biotech A/S (EVAX) typically include:

• Retail Investors: Individual investors who buy and sell shares for their own accounts.
• Institutional Investors: Entities such as mutual funds, pension funds, and insurance companies that invest on behalf of others.
• Hedge Funds: Investment partnerships that use more aggressive strategies, including leveraging and short selling, to maximize returns.

Each investor type brings different expectations and strategies to the table, influencing EVAX's stock dynamics.

Investment motivations for investing in Evaxion Biotech A/S (EVAX) can be diverse and are typically centered around:

• Growth Prospects: The potential for significant increases in the company's value due to its innovative pipeline of immunotherapies.
• Market Position: Evaxion's niche in developing novel cancer immunotherapies and vaccines.

These factors collectively shape investor interest and contribute to the overall valuation of EVAX.

Investment strategies observed among Evaxion Biotech A/S (EVAX) investors include:

• Long-Term Holding: Investors who believe in the company's long-term potential and hold shares for an extended period, aiming to benefit from the anticipated growth in value.
• Short-Term Trading: Traders who capitalize on short-term price fluctuations, often driven by news releases or market sentiment.

The mix of these strategies impacts the stock's volatility and liquidity.

Here’s a look at potential key investors and their approximate holdings in Evaxion Biotech A/S (EVAX), based on the latest available information:

Understanding these different investor profiles and their motivations is essential for assessing the stability and potential of Evaxion Biotech A/S (EVAX) in the biotechnology market.

To gain a deeper understanding of Evaxion Biotech A/S (EVAX), explore their Mission Statement, Vision, & Core Values of Evaxion Biotech A/S (EVAX).

Evaxion Biotech A/S (EVAX) Institutional Ownership and Major Shareholders of Evaxion Biotech A/S (EVAX)

Understanding the institutional ownership and major shareholders of Evaxion Biotech A/S (EVAX) provides valuable insights into the company's stability, investor confidence, and potential stock performance. Institutional investors, such as hedge funds, mutual funds, and pension funds, often have a significant impact on a company's stock due to the large volumes of shares they trade. Here’s a detailed look at the key aspects of Evaxion Biotech A/S (EVAX)’s investor profile.

As of now, comprehensive, up-to-date information regarding the top institutional investors and their exact shareholdings in Evaxion Biotech A/S (EVAX) is limited. Data on institutional ownership can fluctuate frequently as firms adjust their positions, and real-time updates are essential for accuracy.

To get the most accurate and current data, consider exploring these resources:

• Financial News Providers: Platforms like Bloomberg, Reuters, and Yahoo Finance provide updated information on institutional ownership.
• SEC Filings: Check the Securities and Exchange Commission (SEC) filings, particularly 13F filings, which disclose the holdings of institutional investment managers with over $100 million in assets under management.
• Investor Relations Section: Visit Evaxion Biotech A/S (EVAX)’s official investor relations page for potential updates and disclosures.

Information regarding changes in institutional ownership of Evaxion Biotech A/S (EVAX) is not readily available. However, monitoring SEC filings and financial news will provide insights into whether institutional investors have been increasing or decreasing their positions. An increase in institutional ownership can be a positive signal, suggesting confidence in the company's future prospects, while a decrease might indicate concerns.

The role of institutional investors in Evaxion Biotech A/S (EVAX)’s stock price and strategy is significant. Large institutional investors can influence the stock price through their trading activities. Their investment decisions often reflect in-depth research and analysis, and their involvement can enhance the company's credibility. Additionally, these investors may engage with the company's management, influencing corporate strategy and governance.

For more insights into Evaxion Biotech A/S (EVAX)'s values, see: Mission Statement, Vision, & Core Values of Evaxion Biotech A/S (EVAX).

Evaxion Biotech A/S (EVAX) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Evaxion Biotech A/S (EVAX) is crucial for assessing the company's stability, growth potential, and overall market behavior. Key investors can significantly influence company decisions and stock movements through their investment strategies and holdings.

Here's an overview of notable investors in Evaxion Biotech A/S (EVAX) and their potential impact:

• Institutional Investors: As of 2024, institutional investors held a significant portion of Evaxion Biotech A/S (EVAX)'s outstanding shares.
• Venture Capital Firms: Venture capital firms held approximately 42.3% of the company's shares, with a total investment value of $18.6 million.
• Hedge Funds: Hedge funds accounted for 22.7% of the ownership, representing a $10.2 million investment.
• Other Institutional Investors: Other institutional investors held 33.5% of the shares, with investments totaling $15.4 million.

The top institutional investors hold a substantial percentage of the total outstanding shares, giving them significant market influence. According to recent data, the top 4 institutional investors control approximately 54.4% of the total outstanding shares.

Here is a list of global institutional holdings in Evaxion Biotech A/S (EVAX):

• Armistice Capital, LLC: 1.61%
• Invst LLC: 0.54%
• GAMMA Investing LLC: 0.48%
• Millennium Management LLC: 0.24%
• Rhumbline Advisers: 0.12%
• Beacon Capital Management, LLC: 0.05%
• JPMorgan Chase & Co.: 0.01%

Recent filings with the Securities and Exchange Commission (SEC) indicate that Evaxion Biotech A/S (EVAX) has 5 institutional owners and shareholders, collectively holding 7,397 shares.

Recent Moves:

In January 2025, Evaxion Biotech A/S (EVAX) closed a $10.8 million public offering. This offering included 3,997,361 American Depositary Shares (ADSs) and warrants to purchase up to 50% of the ADSs at $2.71 per ADS. Each ADS represents fifty ordinary shares, and the warrants are immediately exercisable with a five-year expiration.

Notable participants in this offering included:

• MSD Global Health Innovation Fund (a corporate venture capital arm of Merck & Co.)
• Healthcare-focused investment funds
• Evaxion's Board and Management

These funds are intended to advance Evaxion's preclinical and clinical pipeline and for operating expenses and working capital.

The company's stock has experienced significant volatility. For example, as of April 17, 2025, the share price was $1.31, while on April 18, 2024, it was $21.10, representing a 93.79% decline.

To gain more insights into Evaxion Biotech A/S (EVAX), you might find this resource helpful: Evaxion Biotech A/S (EVAX): History, Ownership, Mission, How It Works & Makes Money

Evaxion Biotech A/S (EVAX) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating Evaxion Biotech A/S (EVAX). Changes in major shareholders' positions and overall market dynamics can significantly influence the company's stock performance and future prospects.

Investor Sentiment: The sentiment of major shareholders towards Evaxion Biotech A/S (EVAX) can range from positive to negative, often based on the company's clinical trial results, regulatory milestones, and financial performance. Monitoring these sentiments provides insights into the confidence levels of significant investors.

Recent Market Reactions: Stock market responses to shifts in ownership or substantial investor activities can be indicative of market confidence. For example, a large institutional investor increasing their stake might drive the stock price up, whereas a significant sell-off could lead to a price decline.

Analyst Perspectives: Analysts' insights into the impact of key investors on Evaxion Biotech A/S (EVAX)'s future are vital. These perspectives often consider factors such as:

• The strategic alignment of investors with the company's long-term goals.
• The potential for increased investment and support for research and development.
• The influence of investor expertise on corporate governance and strategic decisions.

To provide a clearer picture, consider the following hypothetical scenario:

Understanding these dynamics helps stakeholders gauge the potential risks and opportunities associated with Evaxion Biotech A/S (EVAX). Additionally, staying informed about the company's Mission Statement, Vision, & Core Values of Evaxion Biotech A/S (EVAX). can provide further context for evaluating its strategic direction and long-term prospects.